Kidney Transplantation
Conditions
Keywords
kidney transplantation, ischemia-reperfusion injury, phosphatidylserine binding
Brief summary
The purpose of this study is evaluate the safety and tolerability of Diannexin in kidney transplant recipients.
Detailed description
Ischemia-reperfusion injury, which occurs when the blood supply to an organ, or part of an organ, is cut off and subsequently restored, is an important clinical problem in the organ transplant setting. Diannexin, a recombinant form of the endogenous human Annexin V protein, is in development as a therapeutic agent designed to prevent ischemia-reperfusion injury following organ transplantation. Pharmacology studies indicate that Diannexin has protective effect in various ischemia-reperfusion injury and organ transplantation models. Diannexin binds to phosphatidylserine on cell surfaces, which is believed to underlie its ability to attenuate ischemia-reperfusion injury. In a completed Phase 1 trial, Diannexin was judged safe and well tolerated in healthy adult subjects. The present study is designed to determine the safety and tolerability of single escalating doses of Diannexin in kidney transplant recipients.
Interventions
DRUGDiannexin
single dose, 200 µg/kg IV
DRUGPlacebo
Single dose, IV
Sponsors
CTI Clinical Trial and Consulting Services
Alavita Pharmaceuticals Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Scheduled to receive a kidney transplant from a deceased expanded criterion donor (ECD) or a donor cardiac death (DCD) donor that was exposed to no more than 36 hr of cold ischemia prior to transplantation, or scheduled to receive a kidney transplant from a standard criterion donor (SCD) that was exposed to 24-36 hr of cold ischemia prior to transplantation * Willing to use adequate contraception for at least 4 weeks after dosing * Willing and able to provide written Informed Consent and to comply with the requirements of the study
Exclusion criteria
* If female, subject is pregnant or lactating * Known bleeding diathesis * INR at Screening \> 1.5 * Platelet count at Screening below LLN and judged clinically significant * Use of Plavix, anticoagulants other than aspirin, antithrombotics, and/or blood-thinning agents within 10 days prior to study entry * Previous receipt of an organ transplant * Will receive concurrent transplant of any additional organ(s) * Clinically significant active infection at study entry * Surgery within 2 weeks prior to study entry * Believed to have used an illicit drug and/or abused alcohol within 3 months prior to study entry * Presence of a psychiatric illness that might interfere with study participation * Cancer, other than basal cell or squamous cell cancer of the skin, within 2 years prior to study entry * Scheduled to receive a kidney transplant from a low risk donor * Currently participation, or participated within 30 days prior to study entry, in an investigational drug study * Known allergy to kanamycin * History or presence of any medical condition or disease that could place the subject an unacceptable risk for study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety assessments -- physical examinations, vital signs, clinical safety laboratory tests, ECGs, immunogenicity testing, adverse events | 28 days following administration of study medication |
Secondary
| Measure | Time frame |
|---|---|
| Population pharmacokinetics | Through Hour 48 after dosing |
Countries
United States
Outcome results
None listed